{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"name":"NCT05809752","nct_id":"NCT05809752","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05809752. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"HER2/3 peptide-pulsed DC1 will be administered intrathecally (IT) weekly for 6 doses /cycle for a maximum of two cycles, and then re-staged. If there are sufficient DC1s this may be continued weekly thereafter. There are 1 safety cohort (1 million DCV cells) and 3 escalating doses (2 million, 10 million and 50 million DCV cells) possible.","label":"Dendritic Cell (DC) Vaccine dose escalation","type":"EXPERIMENTAL"}],"collaborators":["United States Department of Defense"],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Leptomeningeal Disease","Triple Negative Breast Cancer","HER2-positive Breast Cancer"],"enrollment":{"count":15,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dendritic Cell Vaccine","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-15","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","official_title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-05-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximum Tolerated Dose of Intrathecal Dendritic Cell Vaccine","timeFrame":"Up to 12 weeks"}],"references":[],"start_date":{"date":"2023-08-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","url":"https://clinicaltrials.gov/study/NCT05809752"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05809752"}